Application of SS-OCTA to evaluate the effects of long-term hydroxychloroquine treatment on retinal structure and microcirculation in patients with systemic lupus erythematosus

Table 2 Comparison of clinical data results between groups of SLE patients

Project	Baseline group (n = 21)	Low-risk group (n = 23)	High-risk group (n = 29)	χ ²/H/F	P-value
SLE course of disease (months)	11.00 (8.00,12.00)	39.00 (29.00,48,00)	96.00 (73.00,120.00)	59.301	0.000^b*
SLEDAI	3.43 ± 0.87	3.00 ± 0.95	3.34 ± 0.94	1.384	0.257
HCQ course of treatment (months)	10.00 (7.00,11.5)	37.00 (29.00,44.00)	96.00 (69.00,115.50)	63.611	0.000^b*
HCQ daily dose(mg)	400.00 (300.00,400.00)	400.00 (200.00,400.00)	200.00 (200.00,350.00)	12.873	0.002^b*
HCQ cumulative dose (g)	96.00 (72.00,138.00)	288.00 (216.00,468.00)	666.0 (414.00,792.00)	52.861	0.000^b*
HCQ concentration (ng/ml)	504.45 ± 270.60	488.36 ± 244.62	416.82 ± 275.08	0.804	0.452
GC (used/ not used)	18/3	23/0	27/2	3.511	0.173^a
GCdose (mg)	4.31 ± 2.61	5.11 ± 1.54	4.45 ± 1.84	1.036	0.360

Note: * Bonferroni-corrected P < 0.016 indicates statistically significant differences. a indictes that the analysis used the χ2 test; b indicates the use of the Kruskal-Wallis H non-parametric test, otherwise, Anova analysis was employed

ISSN: 1471-2415